Blinatumomab Knocks Out Residual Disease

Abstract Recently approved to treat relapsed or refractory Philadelphia chromosome–negative precursor B-cell acute lymphoblastic leukemia, blinatumomab also seems to knock out minimal residual disease in the bone marrow of patients who achieve remission after treatment.